Satellos Bioscience Inc.
corporate_fare Company Profile
Satellos Bioscience Inc. (NASDAQ:MSLE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 15 items for MSLE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-13, rated 7/10. Across its 15 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for MSLE spans 6-K, 40-F.
Recent high-impact activity:
- Satellos Reports Q2 2026 Loss of $11.7M, Cash Runway Through 2027, and Positive TRAILHEAD Data
- Satellos Reports Positive Six-Month Interim Data for SAT-3247 in Adult DMD Patients
- SAT-3247 Shows Positive Six-Month Data in DMD Adults, Reducing Muscle Fat and Improving Effort
- Satellos Bioscience Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Drug
- FDA Grants Fast Track to Satellos' SAT-3247 for Duchenne Muscular Dystrophy
Insider Transactions
MSLE files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.